125 related articles for article (PubMed ID: 17992643)
1. Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population.
Yamagishi S; Adachi H; Takeuchi M; Enomoto M; Furuki K; Matsui T; Nakamura K; Imaizumi T
Horm Metab Res; 2007 Nov; 39(11):845-8. PubMed ID: 17992643
[TBL] [Abstract][Full Text] [Related]
2. Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans.
Enomoto M; Adachi H; Yamagishi S; Takeuchi M; Furuki K; Hino A; Hiratsuka A; Takajo Y; Imaizumi T
Metabolism; 2006 Jul; 55(7):912-7. PubMed ID: 16784963
[TBL] [Abstract][Full Text] [Related]
3. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
Yamagishi S; Adachi H; Nakamura K; Matsui T; Jinnouchi Y; Takenaka K; Takeuchi M; Enomoto M; Furuki K; Hino A; Shigeto Y; Imaizumi T
Metabolism; 2006 Sep; 55(9):1227-31. PubMed ID: 16919543
[TBL] [Abstract][Full Text] [Related]
4. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects.
Uribarri J; Stirban A; Sander D; Cai W; Negrean M; Buenting CE; Koschinsky T; Vlassara H
Diabetes Care; 2007 Oct; 30(10):2579-82. PubMed ID: 17496238
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects.
Tahara N; Yamagishi S; Matsui T; Takeuchi M; Nitta Y; Kodama N; Mizoguchi M; Imaizumi T
Cardiovasc Ther; 2012 Feb; 30(1):42-8. PubMed ID: 20626403
[TBL] [Abstract][Full Text] [Related]
6. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Diabetes Metab Res Rev; 2008 Feb; 24(2):109-14. PubMed ID: 17694504
[TBL] [Abstract][Full Text] [Related]
7. Short-term low calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults.
Gugliucci A; Kotani K; Taing J; Matsuoka Y; Sano Y; Yoshimura M; Egawa K; Horikawa C; Kitagawa Y; Kiso Y; Kimura S; Sakane N
Ann Nutr Metab; 2009; 54(3):197-201. PubMed ID: 19420913
[TBL] [Abstract][Full Text] [Related]
8. Serum advanced glycation end products (AGEs) are associated with insulin resistance.
Tan KC; Shiu SW; Wong Y; Tam X
Diabetes Metab Res Rev; 2011 Jul; 27(5):488-92. PubMed ID: 21337488
[TBL] [Abstract][Full Text] [Related]
9. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study.
Kilhovd BK; Juutilainen A; Lehto S; Rönnemaa T; Torjesen PA; Birkeland KI; Berg TJ; Hanssen KF; Laakso M
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):815-20. PubMed ID: 15692098
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects.
Ueda S; Yamagishi S; Matsui T; Noda Y; Ueda S; Jinnouchi Y; Sasaki K; Takeuchi M; Imaizumi T
Cardiovasc Ther; 2012 Aug; 30(4):249-54. PubMed ID: 21884000
[TBL] [Abstract][Full Text] [Related]
12. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
[TBL] [Abstract][Full Text] [Related]
13. Atherosclerosis is associated with plasminogen activator inhibitor type-1 in chronic haemodialysis patients.
Peng Y; Liu H; Liu F; Ouyang L; Cheng M; Gao L; Pan F; Liu Y; Chen X; Li J
Nephrology (Carlton); 2008 Oct; 13(7):579-86. PubMed ID: 19161364
[TBL] [Abstract][Full Text] [Related]
14. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels.
Asselbergs FW; Williams SM; Hebert PR; Coffey CS; Hillege HL; Navis G; Vaughan DE; van Gilst WH; Moore JH
Thromb Haemost; 2006 Oct; 96(4):471-7. PubMed ID: 17003924
[TBL] [Abstract][Full Text] [Related]
15. A novel advanced glycation index and its association with diabetes and microangiopathy.
Sampathkumar R; Balasubramanyam M; Rema M; Premanand C; Mohan V
Metabolism; 2005 Aug; 54(8):1002-7. PubMed ID: 16092048
[TBL] [Abstract][Full Text] [Related]
16. Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis.
Henkel E; Gallo S; Siegert G; Koehler C; Hanefeld M
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):327-34. PubMed ID: 17473573
[TBL] [Abstract][Full Text] [Related]
17. Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction.
Gray RP; Mohamed-Ali V; Patterson DL; Yudkin JS
Thromb Haemost; 1995 Feb; 73(2):261-7. PubMed ID: 7792741
[TBL] [Abstract][Full Text] [Related]
18. PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children.
Kinik ST; Ozbek N; Yuce M; Yazici AC; Verdi H; Ataç FB
Thromb Haemost; 2008 Feb; 99(2):352-6. PubMed ID: 18278185
[TBL] [Abstract][Full Text] [Related]
19. Plasma advanced glycation end products are decreased in obese children compared with lean controls.
Sebeková K; Somoza V; Jarcusková M; Heidland A; Podracká L
Int J Pediatr Obes; 2009; 4(2):112-8. PubMed ID: 18645732
[TBL] [Abstract][Full Text] [Related]
20. [Relationship of age, sex, body weight, smoking, blood lipids and fibrinolytic activities in healthy subjects].
Xiong X; Wang Z; Zhao S
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(1):65-7. PubMed ID: 11938745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
